Drug Search Results
More Filters [+]

Afimoxifene

Alternative Names: afimoxifene, 4-hydroxytamoxifen, hydroxytamoxifen
Latest Update: 2024-06-21
Latest Update Note: Clinical Trial Update

Product Description

A tamoxifen metabolite with both estrogenic and anti-estrogenic effects. Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/afimoxifene)

Mechanisms of Action: ER Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Ascend
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Afimoxifene

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Mastodynia|Breast Cancer|Ductal Carcinoma|Ductal Breast Carcinoma|Intraductal Noninfiltrating Carcinoma|Soft Tissue Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NU 18B05

P2

Recruiting

Breast Cancer|Intraductal Noninfiltrating Carcinoma|Ductal Breast Carcinoma|Ductal Carcinoma

2024-01-31

NCI-2017-00244

P2

Completed

Soft Tissue Cancer|Breast Cancer

2021-10-26

4WARD Study

P3

Completed

Unknown

2020-11-16

NWU07-9-02

P2

Completed

Breast Cancer|Ductal Breast Carcinoma|Intraductal Noninfiltrating Carcinoma|Ductal Carcinoma

2011-09-01

Recent News Events